

**Pediatric CIRB Meeting Agenda**

**May 9, 2024**

---

**I. Initial Review**

**ALTE2321**, Walking Juntos: Developing and Testing a Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors (Version Date 04/05/24)

---

**II. Initial Review**

**AREN2231**, Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) (Version Date 04/04/24)

---

**III. Continuing Review**

**AALL1621**, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) (Version Date 02/26/24)

---

**IV. Continuing Review**

**AALL1731**, A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) (Version Date 03/19/24)

---

## **V. Continuing Review**

**AAML1831**, A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (Version Date 12/18/23)

---

## **VI. Continuing Review**

**ACNS1821**, A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (Version Date 03/25/24)

---

## **VII. Continuing Review**

**ADVL1622**, Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors (Version Date 04/16/19)

---

## **VIII. Continuing Review**

**AGCT1532**, Phase 3 Accelerated BEP Trial: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors (Version Date 04/22/21)

---

**IX. Continuing Review**

**APEC14B1**, The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study (Version Date 10/20/23)

---

**X. Continuing Review**

**ACNS1723**, A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355) (Version Date 03/20/24)

---